• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

AlzeCure Pharma

4.28 SEK

+8.08 %

Less than 1K followers

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+8.08 %
+245.36 %
+155.19 %
+144.34 %
+107.95 %
+58.25 %
-10.60 %
-30.76 %
-48.39 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Read more
Market cap
590.2M SEK
Turnover
5.51M SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
3rd party
ShowingAll content types

Financial calendar
26.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

23.2.
2027

Annual report '26

Press release6/10/2026, 10:58 AM

Redeye: AlzeCure Pharma: From lab to Lilly – A historic USD1bn validation

AlzeCure Pharma
Regulatory press release6/9/2026, 5:10 AM

AlzeCure Pharma enters into a collaboration and out-licensing agreement with Lilly for Alzheimer’s project

AlzeCure Pharma
Regulatory press release6/5/2026, 6:00 AM

AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document

AlzeCure Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/26/2026, 6:00 AM

NOTICE TO ANNUAL GENERAL MEETING IN AlzeCure Pharma AB

AlzeCure Pharma
Press release5/19/2026, 8:00 AM

AlzeCure Pharma to host live seminar on the pain project TrkA-NAM ACD137 with a focus on osteoarthritis and neuropathic pain

AlzeCure Pharma
Press release5/13/2026, 10:00 AM

AlzeCure Pharma to present at Redeye Investor Forum Online on May 21

AlzeCure Pharma
Press release5/13/2026, 8:00 AM

AlzeCure Pharma to present at ABG Investor Days on May 21

AlzeCure Pharma
Press release5/8/2026, 8:16 AM

Redeye: AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856

AlzeCure Pharma
Press release5/6/2026, 8:00 AM

New scientific article published on TrkA-NAM ACD137 against osteoarthritic pain

AlzeCure Pharma
Regulatory press release5/5/2026, 6:00 AM

AlzeCure publishes its interim report for January – March 2026

AlzeCure Pharma
Regulatory press release4/30/2026, 6:00 AM

Adjusted timeline for the previously communicated rights issue

AlzeCure Pharma
Regulatory press release4/24/2026, 6:00 AM

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure Pharma
Press release4/20/2026, 8:00 AM

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma
Regulatory press release4/8/2026, 6:00 AM

AlzeCure Pharma publishes its Annual Report for 2025

AlzeCure Pharma
Press release4/7/2026, 8:00 AM

AlzeCure Pharma to present at Redeye Healthcare Day on April 14

AlzeCure Pharma
Press release4/1/2026, 8:00 AM

AlzeCure Pharma to present at Redeye Alzheimer's Theme Event on April 9

AlzeCure Pharma
Press release3/19/2026, 7:00 AM

AlzeCure presents new preclinical data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD

AlzeCure Pharma
Press release3/4/2026, 9:00 AM

AlzeCure Pharma to present at Stora Aktiedagarna in Stockholm on March 11

AlzeCure Pharma
Press release3/3/2026, 9:49 AM

Redeye: AlzeCure Pharma (Q4 2025): Focused execution across core development programmes

AlzeCure Pharma
Regulatory press release2/26/2026, 7:00 AM

AlzeCure publishes its Year-end report for January – December 2025

AlzeCure Pharma